Luprorin 4 Injection contains Leuprolide 4 mg, a synthetic nonapeptide analog of gonadotropin-releasing hormone (GnRH). It acts as a potent GnRH agonist, initially stimulating and subsequently downregulating pituitary gonadotropin secretion, leading to decreased production of luteinizing hormone (LH) and follicle-stimulating hormone (FSH). This results in reduced gonadal steroidogenesis, making Luprorin 4 effective in managing hormone-responsive conditions. It is primarily indicated for the treatment of hormone-dependent prostate cancer, endometriosis, uterine fibroids, and central precocious puberty. The injection is administered intramuscularly or subcutaneously as per the prescribing guidelines, with dosage and duration tailored to the specific condition and patient response. Common adverse effects include hot flashes, injection site reactions, decreased libido, and potential bone mineral density reduction with long-term use. Caution is advised in patients with osteoporosis, cardiovascular disease, or a history of hypersensitivity to GnRH analogs. Regular monitoring of hormone levels and clinical status is recommended during therapy. Luprorin 4 Injection should be used under strict medical supervision, ensuring appropriate patient selection and adherence to treatment protocols to optimize therapeutic outcomes and minimize adverse effects.